Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999–2008 and treated with curative intent in the AIDS Malignancy Consortium

References

• Besson C, Goubar A, Gabarre J, . Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339–2344.
   PubMed Web of Science ®Google Scholar
• Engels EA, Goedert JJ. Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future. J Natl Cancer Inst 2005;97:407–409.
   PubMed Web of Science ®Google Scholar
• Little RF. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003;101:4653–4659.
   PubMed Web of Science ®Google Scholar
• Tirelli U, Errante D, Spina M, . Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin’s lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients. Cancer 1996;77:2127–2131.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Moran T, Song L, . Continuous infusion ifosfamide/MESNA with daily etoposide for refractory HIV-associated non-Hodgkin’s lymphoma. Presented at 1998 ASCO Annual Meeting (Los Angeles, CA). Abstract 185.
   Google Scholar
• Levine AM, Tulpule A, Tessman D, . Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial. J Clin Oncol 1997;15:1094–1103.
   PubMed Web of Science ®Google Scholar
• Spina M, Vaccher E, Juzbasic S, . Human immunodeficiency virus-related non-Hodgkin lymphoma: activity of infusional cyclophosphamide, doxorubicin, and etoposide as second-line chemotherapy in 40 patients. Cancer 2001;92:200–206.
   PubMed Web of Science ®Google Scholar
• Bi J, Espina BM, Tulpule A, . High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin’s lymphoma. J Acquir Immune Defic Syndr 2001;28:416–421.
   PubMed Web of Science ®Google Scholar
• Velasquez WS, McLaughlin P, Tucker S, . ESHAP—an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169–1176.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Bertino JR, Glassman JR, . Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol 1999;17:3776–3785.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, . Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Molina A, Krishnan AY, Nademanee A, . High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy. Cancer 2000;89:680–689.
   PubMed Web of Science ®Google Scholar
• Gabarre J, Azar N, Autran B, . High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma. Lancet 2000;355:1071–1072.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Palmer JM, Zaia JA, . HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL). Biol Blood Marrow Transplant 2010;16:1302–1308.
   PubMed Web of Science ®Google Scholar
• Diez-Martin JL, Balsalobre P, Re A, . Comparable survival between HIV + and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. Blood 2009;113:6011–6014.
   PubMed Web of Science ®Google Scholar
• Re A, Michieli M, Casari S, . High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009;114:1306–1313.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, . Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Briere J, Mounier N, . The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011;29:4079–4087.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Kaplan LD, . Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010;115:3008–3016.
   PubMed Web of Science ®Google Scholar
• Boue F, Gabarre J, Gisselbrecht C, . Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin’s lymphoma. J Clin Oncol 2006;24:4123–4128.
   PubMed Web of Science ®Google Scholar
• Blay J, Gomez F, Sebban C, . The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998;92: 3562–3568.
   PubMed Web of Science ®Google Scholar
• Mounier N, Spina M, Gisselbrecht C. Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 2007;136:685–698.
   PubMed Web of Science ®Google Scholar
• Balsalobre P, Diez-Martin JL, Re A, . Autologous stem-cell transplantation in patients with HIV-related lymphoma. J Clin Oncol 2009;27:2192–2198.
   PubMed Web of Science ®Google Scholar
• Lim ST, Karim R, Nathwani BN, . AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol 2005;23: 4430–4438.
   PubMed Web of Science ®Google Scholar
• Wang ES, Straus DJ, Teruya-Feldstein J, . Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. Cancer 2003;98:1196–1205.
   PubMed Web of Science ®Google Scholar
• Noy A, Kaplan L, Lee J. Feasibility and toxicity of a modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL): preliminary results of a prospective multicenter phase II trial of the AIDS Malignancy Consortium (AMC). Blood 2009;114:1415–1416.
   Web of Science ®Google Scholar
• Cortes J, Thomas D, Rios A, . Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002;94:1492–1499.
   PubMed Web of Science ®Google Scholar